



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/919,758	07/31/2001	Xiaowu Liang	GTSYS.003C1	4879

20995 7590 12/22/2003

KNOBBE MARTENS OLSON & BEAR LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER

STRZELECKA, TERESA E

ART UNIT	PAPER NUMBER
----------	--------------

1637

14

DATE MAILED: 12/22/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/919,758

Applicant(s)

LIANG ET AL.

Examiner

Teresa E Strzelecka

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 August 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3,5-12,14-25,27-41 and 43-46 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3,5-12,14-25,27-41 and 43-46 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

Art Unit: 1637

DETAILED ACTION

1. This office action is in response to an amendment filed on August 25, 2003. Claims 1-3 and 5-45 were previously pending. Applicants cancelled claims 13, 26 and 42, amended claims 1, 7, 11, 14, 21, 23, 24, 27, 30, 34, 38, 43 and 44, and added new claim 46. Claims 1-3, 5-12, 14-25, 27-41 and 43-46 are pending and will be examined.
2. Applicants' claim cancellations, amendments and arguments overcame the following: objection to claims 13, 26 and 42 as being non-limiting; rejection of claims 1-3, 5-9, 11, 14, 21-29, 32 and 38-45 under 35 U.S.C. 112, second paragraph; the terminal disclaimer provided by Applicants overcame the double patenting rejection of claims 1, 2, 7, 8, 10, 11, 16 and 21 over the claims of U.S. Patent No. 6,280,977. The art rejections are maintained for reasons given the "Response to Arguments" section.
3. This action is made non-final because of new grounds of rejection regarding new matter.

Terminal Disclaimer

4. The terminal disclaimer filed on August 25, 2003 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of U.S. Patent No. 6,280,977 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Response to Arguments

5. Applicant's arguments filed August 25, 2003 have been fully considered but they are not persuasive.

A) Regarding the rejection of claims 10, 11, 13 and 16 under 35 U.S.C. 102(a) over Cassata et al., Applicants argue that the reference does not teach amplification of the second nucleic acid fragment with a third nucleic acid fragment to form a fourth nucleic acid fragment, because fill-in PCR is not an amplification reaction. However, by its very nature, PCR (polymerase chain

Art Unit: 1637

reaction) is an amplification method. Further, Cassata et al. teach a long-range PCR, which amplifies the whole fragment (= amplifying the third DNA fragment). Therefore this rejection is maintained.

B) Regarding the rejection of claims 1, 2, 5, 6, 10, 12-15, 21, 22 and 29 under 35 U.S.C. 102(b) over Prodromou et al., Applicants argue that Prodromou et al. do not teach the claimed methods, because they teach assembly of synthetic DNA fragments by PCR, rather than amplification of a target sequence. However, since the method is PCR, each of the fragments, for example, fragment 2, is both a target (for fragment 1 primer), and a primer (for a fragment 3 target). Therefore, Prodromou et al. do teach amplification of target sequences. This rejection is maintained.

C) Regarding the following rejections: rejection of claims 3, 20, 23 and 35 over Prodromou et al. and Felgner et al., rejection of claims 7, 8, 17, 18, 24, 25, 36 and 37 over Prodromou et al. and Uhlman et al., rejection of claims 7, 9, 17 and 19 over Prodromou et al. and Goodchild, and rejection of claims 38-43 over Prodromou et al. and Mullis et al., Applicants argue that since Prodromou et al. do not teach target amplification, these rejections are improper. This argument has been addressed above, and was found not persuasive. Therefore these rejections are maintained.

Specification

6. The amendment filed February 12, 2002 is objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. 35 U.S.C. 132 states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: the last sentence of the paragraph starting on page 6, line 26, which

Art Unit: 1637

is "DNA analogs such as phosphorothioate are also contemplated herein (see U.S. Patent No. 5,459,127)".

Applicant is required to cancel the new matter in the reply to this Office Action.

Claim Rejections - 35 USC § 112

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 9, 19, 25, 37 and 45 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn nuclease resistant moieties being phosphorothioates. There is no basis in the specification for these claims. The amendment to specification introducing this subject matter is considered to be a new matter, therefore these claims are not supported by the specification.

Claim Rejections - 35 USC § 102

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

10. Before proceeding with the rejections, it is noted that the term “nucleic acid sequence that confers function” is interpreted in its broadest meaning, i.e., any function that can be assigned to a nucleic acid.

11. Claims 10, 11, 14 and 16 are rejected under 35 U.S.C. 102(a) as being anticipated by Cassata et al. (Gene, vol. 212, p. 127-135, May 1998; cited in the previous office action).

Regarding claim 10, Cassata et al. teach a method of adding a nucleic acid sequence that confers function to a polynucleotide target sequence, the method comprising:

contacting a first nucleic acid fragment with a polynucleotide target sequence, wherein the first nucleic acid fragment comprises a first region of complementarity to a portion of the polynucleotide target sequence and an extension region (Cassata et al. teach construction of a gene fused to a promoter-gfp reporter. The promoter region (= target sequence) is contacted with a 3' primer (=first nucleic acid fragment) has a region complementary to the target sequence and extension region (first box in Fig. 1).);

PCR amplifying the first nucleic acid fragment and the polynucleotide target, to form a second nucleic acid fragment that comprises the polynucleotide target sequence and the extension region (Cassata et al. teach PCR amplification of the 3' primer and the genomic DNA fragment to form a second nucleic acid fragment (long-range PCR step and box 2 in Fig. 1; page 128, last paragraph).);

contacting the second nucleic acid fragment with a third nucleic acid fragment that comprises a region complementary to the extension region and also a nucleic acid sequence that confers function (Cassata et al. teach contacting the amplified fragment (=second nucleic acid fragment) with a linearized vector (=third nucleic acid fragment), which has a region

complementary to the extension region and a GFP reporter gene (= sequence that confers function) (box 2 in Fig. 1; page 128, last paragraph).); and

PCR amplifying the second nucleic acid fragment with the third nucleic acid fragment to form a fourth nucleic acid fragment that comprises the nucleic acid sequence that confers function joined to the polynucleotide target sequence (Cassata et al. teach PCR amplification of the second and third nucleic acid fragments together to form a final product (box 3 in Fig. 1; page 128, last paragraph).).

Regarding claim 11, Cassata et al. teach primers with extension regions not complementary to the target sequence (Fig. 1).

Regarding claim 13, Cassata et al. teach amplification using a polymerase (page 128, sixth paragraph).

Regarding claim 16, Cassata et al. teach matching the extra A added by the polymerase in the junction primer in fill-in PCR (page 132, the end of the second paragraph).

12. Claims 1, 2, 5, 6, 10, 12, 14, 15, 21, 22, 27-29, 30-34 and 46 are rejected under 35 U.S.C. 102(b) as being anticipated by Prodromou et al. (Protein Engineering, vol. 5, pp. 827-829, 1992; cited in the previous office action).

Regarding claim 1, Prodromou et al. teach a method for amplifying a transcriptionally-active polynucleotide, comprising:

PCR-amplifying a first fragment of DNA with a first primer pair, wherein the first primer pair, upon such amplification, adds to first and second ends of the first fragment predetermined first and second regions of complementarity, to form a second DNA fragment having said first region of complementarity at a first end and a second region of complementarity at a second end of said second DNA fragment (Prodromou et al. teach synthesis of human lysozyme gene by recursive PCR

from ten oligonucleotide fragments. The oligonucleotides were 54-86 bases long and contained overlaps of 17-20 bp in length (page 828). Therefore, each of the fragments served as a primer or target for the neighboring fragments (Fig. 1). Therefore, at any point during the amplification reaction, each fragment, except for fragments 1, 2, 9 and 10, is contacted sequentially with two primers, both of which contain regions of complementarity to which the next two primers anneal. For example, in an idealized situation (because in reality all of the intermediates are present at once), a fragment synthesized from fragments 3-8 is contacted with fragments 2 and 9, which have regions of complementarity to fragments 1 and 10.);

providing a promoter-containing sequence and a terminator-containing sequence, said promoter-containing sequence further including a region complementary to said first region of complementarity, and said terminator-containing sequence further including a region complementary to said second region of complementarity, wherein both said promoter-containing sequence and said terminator-containing sequence include an internal nucleotide capable of forming an A-T base pair immediately adjacent to said region of complementarity (Prodromou et al. teach providing fragments 1 and 10, with fragment 1 containing the promoter sequence and fragment 2 containing the terminator sequence (Fig. 2, page 828). Both the first fragment and the tenth fragment contain nucleotides capable of forming an A-T base pair immediately adjacent to the regions of complementarity; Fig. 2.);

joining said promoter-containing sequence to said first end of said second DNA fragment and said terminator-containing sequence to said second end of said second DNA fragment to form said third DNA fragment (Prodromou et al. teach PCR amplifying the fragments, which means, for example amplifying target fragment 2-9 with fragments 1 and 10, joining the promoter and terminator-containing fragments to fragment 2-9 (Fig. 1; page 829, second paragraph; Fig. 3).); and

PCR-amplifying said third DNA fragment (Prodromou et al. teach PCR amplifying the fragments, which includes amplification of the whole gene (page 829, second paragraph).).

Regarding claim 2, Prodromou et al. teach PCR amplifying the fragments, which means, for example amplifying target fragment 2-9 with fragments 1 and 10, joining the promoter and terminator-containing fragments to fragment 2-9 (Fig. 1; page 829, second paragraph; Fig. 3).

Regarding claims 5 and 6, Prodromou et al. teach Vent or Taq polymerase (page 829, first and second paragraphs).

Since claim 21 is broader than claim 10, they will be considered together.

Regarding claims 10 and 21, Prodromou et al. teach a method of adding a nucleic acid sequence that confers function to a polynucleotide target sequence, the method comprising:

contacting first and second nucleic acid fragments with a polynucleotide target sequence, wherein the first nucleic acid fragment comprises a first region of complementarity to a portion of the polynucleotide target sequence and a first extension region, and the second nucleic acid fragment comprises a second region of complementarity to a portion of the polynucleotide target sequence and a second extension region (Prodromou et al. teach synthesis of human lysozyme gene by recursive PCR from ten oligonucleotide fragments. The oligonucleotides were 54-86 bases long and contained overlaps of 17-20 bp in length (page 828). Therefore, each of the fragments served as a primer or target for the neighboring fragments (Fig. 1). The 5'-most fragment contained the promoter sequence and the 3'-most fragment contained the terminator sequence (Fig. 2, page 828). Therefore, at any point during the amplification reaction, each fragment, except for fragments 1, 2, 9 and 10, is contacted sequentially with two sets of primers, both of which contain regions complementary to the fragment and extension regions, to which the next two primers anneal. For example, in an idealized situation (because in reality all of the intermediates are present at once), a

fragment synthesized from fragments 3-8 is contacted with fragments 2 and 9, which have regions complementary to fragments 3 and 8, and extension regions.);

PCR amplifying the first and second nucleic acid fragments and the polynucleotide target sequence, to form an intermediate nucleic acid fragment that comprises the polynucleotide target sequence flanked by the first and second extension regions (Prodromou et al. teach PCR amplifying the fragments, which means, for example amplifying target fragment 3-8 with fragments 2 and 9 (Fig. 1; page 829, second paragraph).);

contacting the intermediate nucleic acid fragment with a third and fourth nucleic acid fragments that respectively comprises a region complementary to the first and second extension regions, wherein one or both of the third and fourth nucleic acid fragments further comprise at least one nucleic acid region that confers function (Prodromou et al. teach contacting the resulting product, fragment 2-9 with fragments 1 and 10, with fragment 1 having a region complementary to the extension region of fragment 2 and comprising a promoter sequence, and fragment 10 having a region complementary to the extension region of fragment 9 and comprising a terminator sequence.); and

PCR amplifying the intermediate nucleic acid fragment with the third and fourth nucleic acid fragments to form a product nucleic acid fragment that comprises one or more functional nucleic acid regions joined to the polynucleotide target sequence (Prodromou et al. teach PCR amplifying the fragments, which means, for example amplifying target fragment 2-9 with fragments 1 and 10, producing a transcriptionally active product (Fig. 1; page 829, second paragraph; Fig. 3).).

Regarding claims 12 and 29, Prodromou et al. teach nucleic acid regions which comprise a promoter and a terminator (fragments 1 and 10, respectively; Fig. 2).

Regarding claims 14, 15, 27 and 28, Prodromou et al. teach Vent or Taq polymerase (page 829, first and second paragraphs).

Regarding claim 22, Prodromou et al. teach the product nucleic acid comprising a promoter and terminator (Fig. 2).

Regarding claim 30, Prodromou et al. teach a reaction mixture (= system for adding a nucleic acid fragment that confers function to a polynucleotide sequence), comprising:

an extension primer pair, each primer of which comprises a region of complementarity to a strand of the polynucleotide target sequence and a predetermined extension region (Prodromou et al. teach a reaction mixture that contains the oligonucleotides with sequences complementary to the target sequence and extension regions, such as oligonucleotides 2-9 (extension primer pairs) (Fig. 1, page 829, second paragraph); and

a 5' biological function conferring nucleic acid fragment and a 3' biological function conferring nucleic acid fragment, each fragment of which comprises a region of complementarity to one of the extension regions, and a biological function conferring polynucleotide sequence that confers biological function, wherein the extension primer pairs are adapted to add the extension regions to a target sequence upon a first PCR procedure, and the function conferring nucleic acid pairs are adapted to add the functional polynucleotide sequences to the target sequence upon a second PCR procedure (Prodromou et al. teach a reaction mixture that contains oligonucleotides 1 and 10, which contain a promoter and a terminator, respectively (= biological function conferring polynucleotides) (Fig. 2). The limitation following "wherein" is an intended use limitation, therefore they do not impose structural limitation upon the claimed product.).

Regarding claims 31-33, Prodromou et al. teach a reaction mixture comprising a Vent polymerase (page 829, second paragraph) and teach using Taq polymerase (page 829, third paragraph).

Regarding claim 34, Prodromou et al. teach a reaction mixture comprising oligonucleotide 1, which comprises a promoter (Fig. 2).

Regarding claim 46, Prodromou et al. teach a reaction mixture comprising oligonucleotide 10, which comprises a terminator (Fig. 2).

Claim Rejections - 35 USC § 103

13. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

14. Claims 3, 20, 23 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Prodromou et al. and Felgner et al. (U. S. Patent No. 6,165,720; cited in the IDS).

A) The teachings of Prodromou et al. are described above. Prodromou et al. teach addition of promoter and terminator to a nucleic acid fragment, but do not teach insertion of the PNA-binding domain.

B) Regarding claims 3, 20, 23 and 35, Felgner et al. teach construction of nucleic acid vectors (or plasmids) containing PNA-binding sites (col. 12, lines 46-67; col. 13, lines 1-26; col. 26, lines 64-67; col. 27, 28; Fig. 8). The PNA-binding sites confer the following properties onto the plasmids: increased transfection efficiency, nuclear localization, transcription activation, endosomal lytic activity and immunostimulatory activity (col. 6, lines 29-47).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have added PNA-binding sites of Felgner et al. to transcriptionally-active nucleic acids of Prodromou et al. The motivation to do so, provided by Felgner et al. would have been that binding of PNA clamps to PNA-binding sites provided nuclease resistance to DNA duplexes (col. 6, lines 48-54).

15. Claims 7, 8, 17, 18, 24, 25, 36 and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Prodromou et al. and Uhlman et al. (U. S. Patent No. 6,063,571).

A) The teachings of Prodromou et al. are described above. Prodromou et al. teach addition of promoter and terminator to a nucleic acid fragment, but do not teach PNA molecules which confer nuclease resistance.

C) regarding claims 7, 8, 17, 18, 24, 25, 36 and 37, Uhlman et al. teach amplification of nucleic acids with DNA/PNA primers, which contain a PNA moiety at the 5' end of the primer. Such primers can be used with temperature-stable polymerases (col. 2, lines 30-49; col. 5, lines 8-46). Uhlman et al. teach that nucleic acid fragments amplified with DNA/PNA primers are resistant to exonucleases (col. 1, lines 32-39).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the DNA/PNA primers of Uhlman et al. in the amplification method of Prodromou et al. The motivation to do so, provided by Uhlman et al., would have been that PNA confers nuclease resistance to a DNA attached to it (col. 1, lines 32-39).

16. Claims 7, 9, 17 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Prodromou et al. and Goodchild (Bioconjugate Chemistry, vol. 1, pp. 165-187, 1990).

A) The teachings of Prodromou et al. are described above. Prodromou et al. teach addition of promoter and terminator to a nucleic acid fragment, but do not teach addition of at least one phosphorothioate during the amplification reaction.

B) Regarding claims 7, 9, 17 and 19, Goodchild teaches oligonucleotides modified with phosphorothioates and nuclease resistance of such oligonucleotides (page 167, the last paragraph, continued on page 168; page 170, paragraphs 3-6; page 175, paragraphs 9-11).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used phosphorothioate-modified oligonucleotides of Goodchild as primers in the amplification reaction of Prodromou et al. The motivation to do so, provided by Goodchild, would have been that phosphorothioates provided nuclease protection to nucleic acids (page 175, paragraphs 12 and 13).

17. Claims 38-41 and 43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Prodromou et al. and Mullis et al. (U.S. Patent No. 4,965,188).

A) Regarding claim 38, Prodromou et al. teach a method of adding a nucleic acid sequence that confers function to a polynucleotide target sequence, the method comprising:

contacting first and second nucleic acid fragments with a polynucleotide target sequence, wherein the first nucleic acid fragment comprises a first region of complementarity to a portion of the polynucleotide target sequence and a first extension region, and the second nucleic acid fragment comprises a second region of complementarity to a portion of the polynucleotide target sequence and a second extension region (Prodromou et al. teach synthesis of human lysozyme gene by recursive PCR from ten oligonucleotide fragments. The oligonucleotides were 54-86 bases long and contained overlaps of 17-20 bp in length (page 828). Therefore, each of the fragments served as a primer or target for the neighboring fragments (Fig. 1). The 5'-most fragment contained the

Art Unit: 1637

promoter sequence and the 3'-most fragment contained the terminator sequence (Fig. 2, page 828). Therefore, at any point during the amplification reaction, each fragment, except for fragments 1, 2, 9 and 10, is contacted sequentially with two sets of primers, both of which contain regions complementary to the fragment and extension regions, to which the next two primers anneal. For example, in an idealized situation (because in reality all of the intermediates are present at once), a fragment synthesized from fragments 3-8 is contacted with fragments 2 and 9, which have regions complementary to fragments 3 and 8, and extension regions.);

PCR amplifying the first and second nucleic acid fragments and the polynucleotide target sequence, to form an intermediate nucleic acid fragment that comprises the polynucleotide target sequence flanked by the first and second extension regions (Prodromou et al. teach PCR amplifying the fragments, which means, for example amplifying target fragment 3-8 with fragments 2 and 9 (Fig. 1; page 829, second paragraph).);

contacting the intermediate nucleic acid fragment with a third and fourth nucleic acid fragments that respectively comprises a region complementary to the first and second extension regions, wherein one or both of the third and fourth nucleic acid fragments further comprise at least one nucleic acid region that confers function (Prodromou et al. teach contacting the resulting product, fragment 2-9 with fragments 1 and 10, with fragment 1 having a region complementary to the extension region of fragment 2 and comprising a promoter sequence, and fragment 10 having a region complementary to the extension region of fragment 9 and comprising a terminator sequence.); and

PCR amplifying the intermediate nucleic acid fragment with the third and fourth nucleic acid fragments to form a product nucleic acid fragment that comprises one or more functional nucleic acid regions joined to the polynucleotide target sequence (Prodromou et al. teach PCR

Art Unit: 1637

amplifying the fragments, which means, for example amplifying target fragment 2-9 with fragments 1 and 10, producing a transcriptionally active product (Fig. 1; page 829, second paragraph; Fig. 3).).

Regarding claims 39 and 40, Prodromou et al. teach a transcriptional functional region being a promoter (on oligonucleotide 1) or a terminator (on oligonucleotide 10) and addition of both to the final gene sequence (Fig. 2).

Regarding claim 43, Prodromou et al. teach amplification using a Vent or Taq polymerase (page 829, first and second paragraphs).

B) Prodromou et al. do not teach amplification of more than one target nucleic acid or separate amplification of different targets.

C) Regarding claim 38, Mullis et al. teach that in polymerase chain reaction more than one target nucleic acid can be amplified using primers specific for each target (col. 3, lines 1-67; col. 4, lines 1-5; col. 13, lines 20-30). The primers may have sequences non-complementary to the target attached at the 5' end of the primers, and the non-complementary sequences may contain promoters, linkers, coding sequences, etc. (col. 6, lines 44-53; col. 19, lines 60-67; col. 20, lines 1-6).

Regarding claim 41, Mullis et al. teach amplification of different target nucleic acids in separate tubes (col. 34, lines 57).

It would have been *prima facie* obvious to one of ordinary skill in the art to have amplified more than one target nucleic acid according to Mullis et al. in the method of gene synthesis of Prodromou et al. The motivation to do so, provided by Mullis et al., was that multiple nucleic acids are produced in large quantities (col. 9, lines 36-41).

18. Claims 44 and 45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Prodromou et al. and Uhlman et al. (U. S. Patent No. 6,063,571).

Regarding claim 44, Prodromou et al. teach a method of adding a nucleic acid sequence that confers function to a polynucleotide target sequence, the method comprising:

contacting first and second nucleic acid fragments with a polynucleotide target sequence, wherein the first nucleic acid fragment comprises a first region of complementarity to a portion of the polynucleotide target sequence and a first extension region, and the second nucleic acid fragment comprises a second region of complementarity to a portion of the polynucleotide target sequence and a second extension region (Prodromou et al. teach synthesis of human lysozyme gene by recursive PCR from ten oligonucleotide fragments. The oligonucleotides were 54-86 bases long and contained overlaps of 17-20 bp in length (page 828). Therefore, each of the fragments served as a primer or target for the neighboring fragments (Fig. 1). The 5'-most fragment contained the promoter sequence and the 3'-most fragment contained the terminator sequence (Fig. 2, page 828). Therefore, at any point during the amplification reaction, each fragment, except for fragments 1, 2, 9 and 10, is contacted sequentially with two sets of primers, both of which contain regions complementary to the fragment and extension regions, to which the next two primers anneal. For example, in an idealized situation (because in reality all of the intermediates are present at once), a fragment synthesized from fragments 3-8 is contacted with fragments 2 and 9, which have regions complementary to fragments 3 and 8, and extension regions.);

PCR amplifying the first and second nucleic acid fragments and the polynucleotide target sequence, to form an intermediate nucleic acid fragment that comprises the polynucleotide target sequence flanked by the first and second extension regions (Prodromou et al. teach PCR amplifying the fragments, which means, for example amplifying target fragment 3-8 with fragments 2 and 9 (Fig. 1; page 829, second paragraph).);

Art Unit: 1637

contacting the intermediate nucleic acid fragment with a third and fourth nucleic acid fragments that respectively comprises a region complementary to the first and second extension regions, wherein one or both of the third and fourth nucleic acid fragments further comprise at least one nucleic acid region that confers function (Prodromou et al. teach contacting the resulting product, fragment 2-9 with fragments 1 and 10, with fragment 1 having a region complementary to the extension region of fragment 2 and comprising a promoter sequence, and fragment 10 having a region complementary to the extension region of fragment 9 and comprising a terminator sequence.); and

PCR amplifying the intermediate nucleic acid fragment with the third and fourth nucleic acid fragments to form a product nucleic acid fragment that comprises one or more functional nucleic acid regions joined to the polynucleotide target sequence (Prodromou et al. teach PCR amplifying the fragments, which means, for example amplifying target fragment 2-9 with fragments 1 and 10, producing a transcriptionally active product (Fig. 1; page 829, second paragraph; Fig. 3)).

B) Prodromou et al. teach addition of promoter and terminator to a nucleic acid fragment, but do not teach PNA molecules which confer nuclease resistance.

C) Regarding claims 44 and 45, Uhlman et al. teach amplification of nucleic acids with DNA/PNA primers, which contain a PNA moiety at the 5' end of the primer. Such primers can be used with temperature-stable polymerases (col. 2, lines 30-49; col. 5, lines 8-46). Uhlman et al. teach that nucleic acid fragments amplified with DNA/PNA primers are resistant to exonucleases (col. 1, lines 32-39).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the DNA/PNA primers of Uhlman et al. in the amplification method of

Prodromou et al. The motivation to do so, provided by Uhlman et al., would have been that PNA confers nuclease resistance to a DNA attached to it (col. 1, lines 32-39).

19. No claims are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa E Strzelecka whose telephone number is (703) 306-5877. The examiner can normally be reached on M-F (8:30-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (703) 308-1119. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

The examiner will move to the new office in Alexandria on January 8, 2004. The new phone number in that office is (571) 272-0789. Gary Benzion will move to the new office on January 22, 2004. His new phone number is (571) 272-0782.

TS
December 17, 2003


JEFFREY FREDMAN
PRIMARY EXAMINER